Biohaven Ltd. Income Tax Expense
Biohaven Ltd. (BHVN) reported Income Tax Expense of $391.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-10
- Biohaven Ltd. income tax expense (benefit) for the quarter ending 2026-06-30 was $391.00K, a 49.81% increase year-over-year.
- Biohaven Ltd. income tax expense (benefit) for the quarter ending 2026-03-31 was $272.00K, a 55.34% decline year-over-year.
- Biohaven Ltd. income tax expense (benefit) for the quarter ending 2025-12-31 was $351.00K, a 631.25% increase year-over-year.
- Biohaven Ltd. income tax expense (benefit) for the quarter ending 2025-09-30 was $221.00K.
- Biohaven Ltd. income tax expense (benefit) for fiscal 2025 was $1.44M, a 96.19% increase from fiscal 2024.
- Biohaven Ltd. income tax expense (benefit) for fiscal 2024 was $735.00K.
- Biohaven Ltd. income tax expense (benefit) for fiscal 2023 was -$1.38M, a 415.75% decline from fiscal 2022.
- Biohaven Ltd. income tax expense (benefit) for fiscal 2022 was $438.00K, a 67.94% decline from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $391.00K 10-Q · filed 2026-08-10 | $663.00K 10-Q · filed 2026-08-10 | $1.01M derived: sum of 3 quarters · filed 2026-08-10 | $1.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $272.00K 10-Q · filed 2026-05-04 | $623.00K derived: sum of 2 quarters · filed 2026-05-04 | $844.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.10M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $351.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $572.00K derived: sum of 2 quarters · filed 2026-03-02 | $833.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.44M 10-K · filed 2026-03-02 |
| 2025-09-30 | $221.00K 10-Q · filed 2025-11-10 | $482.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.09M 10-Q · filed 2025-11-10 | $1.14M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $261.00K 10-Q · filed 2026-08-10 | $870.00K 10-Q · filed 2026-08-10 | $918.00K derived: sum of 3 quarters · filed 2026-08-10 | $859.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $609.00K 10-Q · filed 2026-05-04 | $657.00K derived: sum of 2 quarters · filed 2026-05-04 | $598.00K derived: sum of 3 quarters · filed 2026-05-04 | $775.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$11.00K derived: sum of 2 quarters · filed 2026-03-02 | $166.00K derived: sum of 3 quarters · filed 2026-03-02 | $735.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | -$59.00K 10-Q · filed 2025-11-10 | $118.00K derived: sum of 2 quarters · filed 2025-11-10 | $687.00K 10-Q · filed 2025-11-10 | -$525.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $177.00K 10-Q · filed 2025-08-11 | $746.00K 10-Q · filed 2025-08-11 | -$466.00K derived: sum of 3 quarters · filed 2026-03-02 | -$3.75M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $569.00K 10-Q · filed 2025-05-12 | -$643.00K derived: sum of 2 quarters · filed 2026-03-02 | -$3.93M derived: sum of 3 quarters · filed 2026-03-02 | -$1.75M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$4.50M derived: sum of 2 quarters · filed 2026-03-02 | -$2.32M derived: sum of 3 quarters · filed 2026-03-02 | -$1.38M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$3.29M 10-Q · filed 2024-11-12 | -$1.11M derived: sum of 2 quarters · filed 2024-11-12 | -$171.00K 10-Q · filed 2024-11-12 | -$14.31M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $2.18M 10-Q · filed 2024-08-09 | $3.12M 10-Q · filed 2024-08-09 | -$11.03M derived: sum of 3 quarters · filed 2025-03-03 | -$9.81M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $939.00K 10-Q · filed 2024-05-09 | -$13.20M derived: sum of 2 quarters · filed 2025-03-03 | -$11.99M derived: sum of 3 quarters · filed 2025-03-03 | -$5.88M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$14.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$12.93M derived: sum of 2 quarters · filed 2025-03-03 | -$6.82M derived: sum of 3 quarters · filed 2025-03-03 | $438.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.22M 10-Q · filed 2023-11-14 | $7.33M derived: sum of 2 quarters · filed 2023-11-14 | $14.58M 10-Q · filed 2023-11-14 | $17.04M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $6.11M 10-Q · filed 2023-07-31 | $13.37M 10-Q · filed 2023-07-31 | $15.82M derived: sum of 3 quarters · filed 2024-02-29 | $14.69M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $7.25M 10-Q · filed 2023-05-12 | $9.71M derived: sum of 2 quarters · filed 2024-02-29 | $8.58M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.32M derived: sum of 2 quarters · filed 2024-02-29 | $1.37M 10-K · filed 2024-02-29 | |
| 2021-09-30 | -$1.13M 10-Q · filed 2022-11-09 | -$1.09M 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |